EC steps up research funding with 120 million euros for 11 new projects to tackle the virus and its variants

23 July 2021

The European Commission has short-listed 11 new projects worth 120 million euros ($140 million) from Horizon Europe, the biggest European research and innovation program (2021-2027), for supporting and enabling urgent research into the coronavirus and its variants.

This funding is part of a wide range of research and innovation actions taken to fight the coronavirus and contributes to the Commission's overall action to prevent, mitigate and respond to the impact of the virus and its variants, in line with the new European bio-defence preparedness plan HERA Incubator.

The 11 short-listed projects involve 312 research teams from 40 countries, including 38 participants from 23 countries outside of the European union.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK